Victoza (Liraglutide) is a long-acting glucagon-like peptide-1 receptor agonist. The U.S. Food and Drug Administration (FDA) approved it on January 25, 2010. It is manufactured by Danish drug maker Novo Nordisk and was launched in the U.S. in February 2010 and in the EU in July 2009.
It acts by binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. It mimics the GLP-1 (glucagon-like peptide-1) hormone and controls the blood glucose level when given along with diet and exercise, in adult patients with Type 2 diabetes mellitus. The injectable form works by stimulating insulin production.